Category: NOVEL DISCOVERIES - Page 13 - Start Medical Product Development

Cell-free treatment reduces brain damage and improves recovery after stroke in mice

October 6, 2026

Ischemic stroke can leave lasting neurological damage after the initial vascular event, with oxidative stress, neuroinflammation, neuronal death and disruption of neural connectivity contributing to impaired recovery. Although current interventions provide partial protection, their ability to prevent delayed neuronal injury remains limited, highlighting a major barrier to functional recovery.

Virtual patients could help flag medical device risks missed by conventional studies

October 5, 2026

University of Manchester–led researchers have unveiled a roadmap for making computer-generated evidence trustworthy enough to help regulators decide whether medical devices are safe and effective, alongside laboratory and clinical evidence.

Candy-coated Lollylab checks saliva for medication

October 5, 2026

What if checking medication levels were as simple as enjoying a lollipop? A candy-coated device called Lollylab could provide the answer. In ACS Sensors, researchers describe how the lollipop’s stem transfers saliva to a sensor that measures acetaminophen levels.

New technology advances understanding of eye pressure and glaucoma

October 4, 2026

For millions of people at risk of glaucoma, healthy eye pressure can mean the difference between preserving vision and losing it. Yet despite decades of research, scientists still do not fully understand what regulates daily changes in eye pressure or how those fluctuations may contribute to glaucoma.

RNA urine test outperforms standard bladder cancer tests and could help guide treatment

October 2, 2026

A simple urine test devised by researchers at Stanford Medicine and the VA Palo Alto Health Care System can diagnose bladder cancer more accurately than current standard methods. The test also allows physicians not only to assess the cancer’s response to treatment but also to predict whether immunotherapy or chemotherapy is likely to be most effective for each patient.

Inflammation can reactivate ‘sleeping’ cancer cells hidden in the bone

October 2, 2026

The spread of cancer from a primary tumor to another place in the body, called metastasis, remains one of the greatest challenges in cancer treatment and is responsible for most cancer-related deaths.

Magnetic therapy headset shows improved cognitive function and mood in people with long COVID

October 1, 2026

A new study led by researchers from the Icahn School of Medicine at Mount Sinai and published in Brain Communications found that a transcranial low-amplitude magnetic field intervention delivered twice weekly into the brain through a noninvasive headset was associated with improvements in several measures of cognitive function and emotional well-being in people experiencing cognitive impairment associated with long COVID.

‘Mini-brains’ model myelin damage and regeneration, offering new tool for MS drug testing

October 1, 2026

Researchers have developed 3D “mini-brains” they hope will help speed up the search for much-needed drug treatments for multiple sclerosis (MS), an autoimmune condition affecting almost 3 million people worldwide. Their research has been published in the journal Nature Neuroscience.

Discovery explains how immune cells target DNA mutations to improve antibodies

October 1, 2026

Scientists at the Montreal Clinical Research Institute (IRCM), led by Université de Montréal medical professor Javier Di Noia, have shed light on a fundamental mystery in immunology: How do immune cells manage to concentrate a powerful mutagenic enzyme at precisely defined regions of DNA while largely sparing the rest of the genome from potentially dangerous damage?

Lung cancers can use two different mechanisms to evade KRAS-inhibiting drugs

September 30, 2026

About 25% of lung adenocarcinomas have mutations of the gene KRAS, which drives uncontrolled cell growth. In recent years, the FDA has approved two KRAS inhibitors to treat patients with KRAS mutations. While these drugs can work well initially, tumors almost always develop resistance to them.